Lantheus Holdings, Inc. reported a revenue of $388.2 million for the second quarter of 2026, reflecting a 2.7% increase from $378.0 million in the same period of 2025. For the first half of 2026, total revenue reached $765.5 million, up 2.0% from $750.8 million year-over-year. The company’s net income for the second quarter was $75.0 million, a decrease of 4.7% compared to $78.8 million in the prior year. However, net income for the first half of 2026 increased by 27.5% to $193.4 million from $151.7 million in the first half of 2025. The earnings per share for the second quarter were $1.15 on a basic basis and $1.11 on a diluted basis.
The company experienced significant changes in its operational structure following the sale of its SPECT business to SHINE Technologies on January 1, 2026. This divestiture led to a reclassification of revenue streams, with Lantheus now categorizing its revenues into Oncology, Neurology, Cardiology, and Strategic Partnerships and Other Revenue. The sale resulted in a gain of $59.5 million for the first half of 2026, which was a notable contributor to the overall financial performance. Additionally, the company reported a substantial increase in sales and marketing expenses, which rose by 101.8% to $82.8 million in the second quarter, primarily due to a $30 million obligation related to the repurchase of the DEFINITY license in China.
In terms of operational metrics, Lantheus reported a gross profit of $241.9 million for the second quarter of 2026, slightly up from $241.0 million in the same quarter of 2025. The company’s total operating expenses decreased by 7.5% to $141.6 million in the second quarter, driven by a significant reduction in general and administrative expenses, which fell by 69% to $20.6 million. The company’s cash and cash equivalents increased to $593.3 million as of June 30, 2026, compared to $359.1 million at the end of 2025, indicating improved liquidity.
Looking ahead, Lantheus is focused on the commercialization of its newly approved PYLARIFY TruVu and the ongoing development of its investigational products, including LNTH-2501 and MK-6240. The company has also entered into a merger agreement with Curium US Holdings LLC, which is expected to close in the first half of 2027, subject to regulatory approvals. This strategic move is anticipated to enhance Lantheus's market position and operational capabilities in the radiopharmaceutical sector. The company remains committed to expanding its product offerings and optimizing its operational efficiencies to drive future growth.
About Lantheus Holdings, Inc.
Lantheus Holdings, Inc. is a leading provider of radiopharmaceuticals and diagnostic imaging products. Its core activities include developing, manufacturing, and marketing radiopharmaceuticals for oncology and cardiology, such as PYLARIFY and DEFINITY. The company serves healthcare providers worldwide, offering products that improve disease detection, characterization, and patient outcomes through advanced imaging and therapeutic solutions. Its business model combines product sales, strategic partnerships, and clinical development.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.
View the complete official filing on the SEC website.
Read on SEC.gov